Clinical Trial

A Remote Physical Activity Program in the Population Suffering from Type 1 Myotonic Dystrophy

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 28, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The COVID-19 pandemic exacerbates health problems by reducing access to adapted and advanced physical rehabilitation for several people who need rehabilitation services, including the population with myotonic dystrophy type 1 (DM1). The PACE tool, an innovative web tool integrating pragmatic physical activity programs, seems to be an interesting and innovative intervention to counter physical deficiencies of people with DM1, which are unfortunately accentuated by the pandemic, while reducing the risk of COVID-19 exposure. Objectives: 1) Evaluate the feasibility, usability and acceptability of the PACE tool in the DM1 population; 2) Evaluate the effects of the intervention on their physical and cognitive health; and 3) Estimate the cost-effectiveness ratio of this intervention. Method: Sixty people (experimental group = 40 and control group = 20) will participate in this randomized intervention study. Participants in the experimental group will be assigned to one of the 35 physical activity programs adapted to their condition of the PACE tool. The program must be performed on a daily basis for a period of 12 weeks. Physical and cognitive health will be assessed before and after the remote intervention via ZOOM, for all participants.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-10-05; most recent amendment 2025-03-24.
Status change: Recruiting → Active, Not Recruiting 2025-03-24
Trial Details
NCT Number NCT05072288
Lead Sponsor Université du Québec à Chicoutimi
Conditions Myotonic Dystrophy Type 1 (DM1)
Enrollment 40 participants
Start Date 2021-08-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-28